Filing Details

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

Silence Therapeutics plc

(Name of Issuer)

Ordinary Shares, nominal value £0.05 per share

(Title of Class of Securities)

 

G8128Y157

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of This Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

	¨	Rule 13d-1(b)
	x	Rule 13d-1(c)
	¨	Rule 13d-1(d)

 

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

13G

 

CUSIP No. G8128Y157

 

1.		NAMES OF REPORTING PERSONS   TCG Crossover GP I, LLC
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION   Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5.		SOLE VOTING POWER   0
		6.		SHARED VOTING POWER   6,314,625 (1)
		7.		SOLE DISPOSITIVE POWER   0
		8.		SHARED DISPOSITIVE POWER   6,314,625 (1)

9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   6,314,625 (1)
10.		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)   ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)   5.9% (2)
12.		TYPE OF REPORTING PERSON (see instructions)   OO

 

(1)

Consists of 6,314,625 Ordinary Shares (as defined in Item 2(d) below) of the Issuer (as defined in Item 1(a) below) held of record by TCG Crossover I (as defined in Item 2(a) below), represented by 2,104,875 American Depositary Shares (“ADSs”), each of which represents, and at the holder’s option is convertible into, three Ordinary Shares.  TCG Crossover GP I (as defined in Item 2(a) below) is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities.

(2)	Based on 107,680,012 Ordinary Shares outstanding as of September 30, 2022, as set forth in the Issuer’s Form 6-K filed with the Securities and Exchange Commission on November 10, 2022 (the “Form 6-K”).

 

 

13G

 

CUSIP No. G8128Y157

 

1.		NAMES OF REPORTING PERSONS   TCG Crossover Fund I, L.P.
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION   Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5.		SOLE VOTING POWER   0
		6.		SHARED VOTING POWER   6,314,625 (1)
		7.		SOLE DISPOSITIVE POWER   0
		8.		SHARED DISPOSITIVE POWER   6,314,625 (1)

9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   6,314,625 (1)
10.		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)   ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)   5.9% (2)
12.		TYPE OF REPORTING PERSON (see instructions)   PN

 

(1)

Consists of 6,314,625 Ordinary Shares of the Issuer held of record by TCG Crossover I, represented by 2,104,875 ADSs, each of which represents, and at the holder’s option is convertible into, three Ordinary Shares.  All such securities are held of record by TCG Crossover I. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities.

(2)	Based on 107,680,012 Ordinary Shares outstanding as of September 30, 2022, as set forth in the Form 6-K.

 

 

13G

 

CUSIP No. G8128Y157

 

1.		NAMES OF REPORTING PERSONS   Chen Yu
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION   United States of America

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5.		SOLE VOTING POWER   0
		6.		SHARED VOTING POWER   6,314,625 (1)
		7.		SOLE DISPOSITIVE POWER   0
		8.		SHARED DISPOSITIVE POWER   6,314,625 (1)

9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   6,314,625 (1)
10.		CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)   ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)   5.9% (2)
12.		TYPE OF REPORTING PERSON (see instructions)   IN

 

(1)

Consists of 6,314,625 Ordinary Shares of the Issuer held of record by TCG Crossover I, represented by 2,104,875 ADSs, each of which represents, and at the holder’s option is convertible into, three Ordinary Shares.  All such securities are held of record by TCG Crossover I. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities.

(2)	Based on 107,680,012 Ordinary Shares outstanding as of September 30, 2022, as set forth in the Form 6-K.

 

 

13G

 

CUSIP No. G8128Y157

 

Explanatory Note

 

This Amendment No. 1 amends and restates the statement on Schedule 13G filed by TCG Crossover Management, LLC with the Securities and Exchange Commission on August 19, 2022.

 

Item 1(a).

Name of Issuer:

 

Silence Therapeutics plc (the “Issuer”).

 

Item 1(b).

Address of Issuer’s Principal Executive Offices:

 

72 Hammersmith Road

London W14 8TH

United Kingdom

 

Item 2(a).

Name of Person Filing:

 

This joint statement on Schedule 13G is being filed by TCG Crossover Fund I, L.P. (“TCG Crossover I”), TCG Crossover GP I, LLC (“TCG Crossover GP I” and together with TCG Crossover I, the “Reporting Entities”) and Chen Yu (the “Reporting Individual”). The Reporting Entities and the Reporting Individual are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to this Statement as Exhibit 1. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person’s pecuniary interest therein.

 

Item 2(b)

Address of Principal Business Office, or if None, Residence:

 

The address of the principal business office of each Reporting Person is 705 High St., Palo Alto, CA 94301.

 

Item 2(c).

Citizenship:

 

TCG Crossover GP I is a limited liability company organized under the laws of the State of Delaware. TCG Crossover I is a limited partnership organized under the laws of the State of Delaware. The Reporting Individual is a citizen of the United States of America.

 

Item 2(d).

Title of Class of Securities:

 

Ordinary Shares, £0.05 par value per share (“Ordinary Shares”).

 

Item 2(e).

CUSIP Number:

 

G8128Y157

 

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

 

Not applicable.

 

 

13G

 

CUSIP No. G8128Y157

 

Item 4.

Ownership.

 

(a) Amount beneficially owned:

 

See Row 9 of the cover page for each Reporting Person and the corresponding footnotes.*

 

(b) Percent of class:

 

See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*

 

(c) Number of shares as to which the person has:

 

(i) Sole power to vote or to direct the vote

 

See Row 5 of the cover page for each Reporting Person and the corresponding footnotes.*

 

(ii) Shared power to vote or to direct the vote

 

See Row 6 of the cover page for each Reporting Person and the corresponding footnotes.*

 

(iii) Sole power to dispose or to direct the disposition of

 

See Row 7 of the cover page for each Reporting Person and the corresponding footnotes.*

 

(iv) Shared power to dispose or to direct the disposition of

 

See Row 8 of the cover page for each Reporting Person and the corresponding footnotes.*

 

*	Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such Ordinary Shares, except for the shares, if any, such Reporting Person holds of record.

 

Item 5.

Ownership of Five Percent or Less of a Class.

 

Not applicable.

 

Item 6.

Ownership of More Than Five Percent on Behalf of Another Person.

 

Under certain circumstances set forth in the limited partnership agreements of TCG Crossover I and the limited liability company agreement of TCG Crossover GP I, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

 

Not applicable.

 

Item 8.

Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9.

Notice of Dissolution of the Group.

 

Not applicable.

 

Item 10.

Certifications.

 

Not Applicable.

 

Material to be Filed as Exhibits.

Exhibit 1 – Joint Filing Agreement.

 

 

13G

 

CUSIP No. G8128Y157

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 14, 2023

 

 

TCG Crossover Fund I, L.P.
By:	TCG Crossover GP I, LLC
Its:	General Partner

 

By:	/s/ Chen Yu
	Managing Member
TCG Crossover GP I, LLC
By:	/s/ Chen Yu
	Managing Member
Chen Yu
/s/ Chen Yu

 

 

Exhibit 1

JOINT FILING AGREEMENT

 

The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the timely filing of such statement on Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness or accuracy of the information concerning the others of the undersigned, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate or incomplete. This Joint Filing Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

 

Dated: February 14, 2023

 

 

TCG Crossover Fund I, L.P.
By:	TCG Crossover GP I, LLC
Its:	General Partner

 

By:	/s/ Chen Yu
	Managing Member
TCG Crossover GP I, LLC
By:	/s/ Chen Yu
	Managing Member
Chen Yu
/s/ Chen Yu

 

 

8